Zanidatamab beat trastuzumab head-to-head in first-line HER2-positive gastroesophageal cancer. How to choose among 14 HER2-directed antibodies, with Yara Abdou, MD.

A single-center randomized trial paired a checkpoint inhibitor with a four-drug chemotherapy backbone in pancreatic tumors ...

As study after study reveals unexpected health benefits of GLP-1s, longevity researchers are launching trials to examine the ...

As the US military moves forward with plans to routinely measure testosterone in male servicemembers aged ≥ 30 years, a cross ...

Can rectal tone reliably help diagnose cauda equina syndrome? Amal Mattu, MD, challenges a long-standing practice and ...